Lowering of amyloid beta peptide production with a small molecule inhibitor of amyloid-β precursor protein

Pauline Pl So1, Ella Zeldich, Kathleen I Seyb

  • 1Department of Medicine Graduate Program in Molecular Medicine, Boston University School of Medicine, Boston, MA, USA.

Insights

Researchers screened compounds to find molecules that inhibit amyloid precursor protein (APP) dimerization. Two inhibitors reduced amyloid-beta (Aβ) production, suggesting APP dimerization modulation as a potential Alzheimer's disease therapy.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid plaques formed from amyloid-beta (Aβ) peptides.
  • Amyloid precursor protein (APP) processing is central to Aβ production.
  • The role of APP dimerization in Aβ generation remains unclear.

Purpose of the Study:

  • To identify small molecules that modulate APP dimerization.
  • To investigate the impact of APP dimerization on Aβ production.

Main Methods:

  • High-throughput screening (HTS) using APP-Firefly luciferase complementation assay.
  • Testing identified modulators for effects on Aβ generation via ELISA.
  • Analysis of sAPPα, sAPPβ, and γ-CTF levels.

Main Results:

  • Identified two small molecules that inhibit APP dimerization.
  • These inhibitors reduced Aβ levels without altering sAPPα or γ-CTF.
  • Inhibitors lowered sAPPβ levels, indicating reduced β-secretase cleavage.

Conclusions:

  • This is the first HTS for small molecule modulators of APP dimerization.
  • Inhibition of APP dimerization reduces Aβ production.
  • Modulating APP dimerization is a potential therapeutic strategy for Alzheimer's disease.